Tubulitis in a patient treated with nivolumab: Case report and literature review
Journal of Onco-Nephrology · 2018
DOI: 10.1177/2399369318812969 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Onco-Nephrology, 2018. Verfasst von Viral Vakil und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Kidney injury associated with use of immune checkpoint inhibitors that target the programmed death-1 molecule commonly manifests as acute tubulointerstitial nephritis on kidney biopsy. We present a case of a 66-year-old man who developed acute kidney injury at 6 months after initiation of treatment with anti-programmed death-1 antibody, nivolumab, for treatment of metastatic urothelial carcinoma. A renal biopsy showed focal moderate-to-severe lymphocytic tubulitis with minimal interstitial inflammation. Programmed death ligand-1 immunopositivity was detected only in tubules exhibiting lymphocytic tubulitis. The patient’s renal function improved to baseline with conservative management consisting of discontinuation of nivolumab followed by prednisone treatment.
Zitieren
APA
Vakil, V., Birkenbach, M., Woerner, K., & Bu, L. (2018). Tubulitis in a patient treated with nivolumab: Case report and literature review. Journal of Onco-Nephrology. https://doi.org/10.1177/2399369318812969
Vancouver
Vakil V, Birkenbach M, Woerner K, Bu L. Tubulitis in a patient treated with nivolumab: Case report and literature review. Journal of Onco-Nephrology. 2018. doi:10.1177/2399369318812969
BibTeX
@article{Vakil2018,
author = {Vakil, Viral and Birkenbach, Mark and Woerner, Katti and Bu, Lihong},
title = {Tubulitis in a patient treated with nivolumab: Case report and literature review},
journal = {Journal of Onco-Nephrology},
year = {2018},
doi = {10.1177/2399369318812969}
}
EUVIMED